The global vascular patches market size was valued at USD 505.1 million in 2025 and is projected to grow from USD 534.1 million in 2026 to USD 842.7 million by 2033, at a CAGR of 6.7% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 36.1% in 2025. The rising prevalence of peripheral artery disease, carotid artery disease, diabetes, and other atherosclerotic conditions, particularly among older adults, is increasing the need for vascular interventions. The use of vascular patches in endarterectomy, peripheral vascular reconstruction, arterial repair, and arteriovenous access revisions further supports market demand.
The increasing prevalence of peripheral artery disease (PAD), carotid artery disease, and atherosclerosis is creating a larger patient pool requiring vascular interventions. PAD causes narrowing or blockage of peripheral arteries and can progress to severe limb complications, increasing the need for revascularization and arterial repair. This growing disease burden is expected to support demand for vascular patches used in arterial reconstruction and repair. According to the American Limb Preservation Society (ALPS), the study published in Research projects a 220% increase in global peripheral artery disease (PAD) cases, rising from 113 million in 2021 to more than 360 million by 2050.
“What we found is both alarming and actionable,” said Dr. Wuquan Deng, senior author of the study and professor at Chongqing University Central Hospital and King’s College London. “If current trends continue, we are facing a doubling of PAD mortality and a staggering 68% rise in disability burden. Yet, by prioritizing aggressive management of diabetes, obesity, and hypertension, we could prevent over 30% of this burden.”
“This is a call to action,” said Dr. David G. Armstrong, co-author and Distinguished Professor of Surgery and Neurological Surgery with the Keck School of Medicine of USC. “PAD is the tip of a much larger metabolic iceberg. If we act decisively, we can not only prevent disease but reduce amputations and deaths. This study gives us a roadmap-and a responsibility-to do so.” He is also a podiatric surgeon with Keck Medicine of USC.
The continued use of peripheral vascular reconstruction, endarterectomy, arterial repair, and patch angioplasty is driving demand for vascular patches. FDA documentation confirms that vascular repair patches are used in the reconstruction of the carotid, renal, iliac, femoral, profunda, and tibial vessels, as well as arteriovenous access revisions. The broad range of surgical applications provides a stable clinical basis for the adoption of vascular patches.
Furthermore, advancements in biologic vascular patches, particularly bovine pericardial and decellularized tissue materials, are improving biocompatibility, handling, durability, and tissue integration. Products such as VASCU-GUARD and XenoSure demonstrate the established use of biologic patches for vascular reconstruction and repair, including peripheral vascular procedures. Continued development of biologic materials is expected to strengthen their adoption across vascular surgery.
For instance, in July 2026, Medical Xpress reported a technological advancement in vascular patch development involving vascular organoid patches for treating ischemic heart disease. Researchers at Stanford University developed vascular organoids from human cells and surgically implanted them onto the surface of the hearts of pigs with ischemic heart disease. The patches survived for several weeks, promoted the formation of new microvessels, increased vessel density and maturity, and improved blood flow and cardiac function. The technology combines endothelial progenitor cells with mesenchymal stem cell-derived smooth muscle cells, offering a regenerative approach that could expand vascular patch applications beyond conventional structural repair toward biological tissue regeneration.
The increasing prevalence of peripheral artery disease (PAD), carotid artery disease, and atherosclerosis is creating a larger patient pool requiring vascular interventions. PAD causes narrowing or blockage of peripheral arteries and can progress to severe limb complications, increasing the need for revascularization and arterial repair. This growing disease burden is expected to support demand for vascular patches used in arterial reconstruction and repair. According to the American Limb Preservation Society (ALPS), the study published in Research projects a 220% increase in global peripheral artery disease (PAD) cases, rising from 113 million in 2021 to more than 360 million by 2050.
“What we found is both alarming and actionable,” said Dr. Wuquan Deng, senior author of the study and professor at Chongqing University Central Hospital and King’s College London. “If current trends continue, we are facing a doubling of PAD mortality and a staggering 68% rise in disability burden. Yet, by prioritizing aggressive management of diabetes, obesity, and hypertension, we could prevent over 30% of this burden.”
“This is a call to action,” said Dr. David G. Armstrong, co-author and Distinguished Professor of Surgery and Neurological Surgery with the Keck School of Medicine of USC. “PAD is the tip of a much larger metabolic iceberg. If we act decisively, we can not only prevent disease but reduce amputations and deaths. This study gives us a roadmap-and a responsibility-to do so.” He is also a podiatric surgeon with Keck Medicine of USC.
The continued use of peripheral vascular reconstruction, endarterectomy, arterial repair, and patch angioplasty is driving demand for vascular patches. FDA documentation confirms that vascular repair patches are used in the reconstruction of the carotid, renal, iliac, femoral, profunda, and tibial vessels, as well as arteriovenous access revisions. The broad range of surgical applications provides a stable clinical basis for the adoption of vascular patches.
Furthermore, advancements in biologic vascular patches, particularly bovine pericardial and decellularized tissue materials, are improving biocompatibility, handling, durability, and tissue integration. Products such as VASCU-GUARD and XenoSure demonstrate the established use of biologic patches for vascular reconstruction and repair, including peripheral vascular procedures. Continued development of biologic materials is expected to strengthen their adoption across vascular surgery.
For instance, in July 2026, Medical Xpress reported a technological advancement in vascular patch development involving vascular organoid patches for treating ischemic heart disease. Researchers at Stanford University developed vascular organoids from human cells and surgically implanted them onto the surface of the hearts of pigs with ischemic heart disease. The patches survived for several weeks, promoted the formation of new microvessels, increased vessel density and maturity, and improved blood flow and cardiac function. The technology combines endothelial progenitor cells with mesenchymal stem cell-derived smooth muscle cells, offering a regenerative approach that could expand vascular patch applications beyond conventional structural repair toward biological tissue regeneration.
Global Vascular Patches Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global vascular patches market report based on material, application, surgery, end-use, and region:Material Outlook (Revenue, USD Million, 2021 - 2033)
- Biologic
- Synthetic
- Biosynthetic
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Carotid Endarterectomy
- Peripheral Artery Reconstruction
- Aortic & Cardiac / Congenital Repair
- Hemodialysis / AV Access Surgery
- Trauma & Other Vascular Repairs
Surgery Outlook (Revenue, USD Million, 2021 - 2033)
- Open Surgery
- Hybrid Surgery
End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Specialty Cardiac & Vascular Centers
- Ambulatory Surgical Centers
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Vascular Patches Market Variables, Trends & Scope
Chapter 4. Vascular Patches Market: Material Estimates & Trend Analysis
Chapter 5. Vascular Patches Market: Application Estimates & Trend Analysis
Chapter 6. Vascular Patches Market: Surgery Estimates & Trend Analysis
Chapter 7. Vascular Patches Market: End Use Estimates & Trend Analysis
Chapter 8. Vascular Patches Market: Regional Estimates & Trend Analysis by Material, Application, Surgery, and End Use
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Vygon
- Baxter International Inc.
- LeMaitre Vascular, Inc.
- W. L. Gore & Associates, Inc.
- Getinge AB
- B. Braun Melsungen AG
- Artivion, Inc.
- Edwards Lifesciences Corporation
- Elutia Inc. (formerly Aziyo Biologics)
- Becton, Dickinson and Company (BD)
- Labcor Laboratórios Ltda.
- VUP Medical a.s.
- Aegis Lifesciences Pvt. Ltd.
